New Products to Add 100 bn Dollars of Value to Pharma Market, Reports Kalorama Information

13 Sep 2012 • by Natalie Aster

New products will add $100 billion to an ailing global pharmaceutical market by 2016. There are an estimated 724 projects in development from the top 50 pharma companies which have the potential to augment the total pharmaceutical market.

While not all drug products in development will be approved and marketed, the new market study “Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016” by Kalorama Information states that biopharmaceutical products represent a good number of those new products. Cancer treatments represent the highest percentage of new drugs, due to increased cases and favorable reimbursement trends by payors.

“Drugs in the oncology segment are expected to make a significant impact on current markets,” said Melissa Elder, Kalorama Information analyst and author of the report. “New entrants will increase competition and provide advanced alternatives to current therapies.”

According the report, the growing interest in biotechnology development has transitioned an industry referred to as pharmaceutical to biopharmaceutical in less than a decade. Companies such as Pfizer have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Companies such as Amgen, which specializes in biotechnology, now compete with a growing number of biopharmaceutical companies and the line between pharmaceutical and biotechnology specialty companies is becoming more blended; this trend is expected to keep growing.

Report Details:

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016
Published: August, 2012
Pages: 220
Price: US$ 2.500,00

The pharmaceutical companies included in the top 50 generate about $825 billion in annual revenues. When comparing sales for prescription biopharmaceuticals, Pfizer, Merck, Novartis, Sanofi-Aventis and Roche are among the leaders in the industry, according to the report.

The report takes a deeper look at the top 50 companies, what products are in their pipeline, and when they may be released. It suggests that a reasonable amount of approvals could boost a pharmaceutical industry suffering from patent expirations.

More information can be found in the report “Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016” by Kalorama Information.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com